Geschwind M D, Skolasky R I, Royal W S, McArthur J C
Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
J Neurovirol. 2001 Aug;7(4):353-7. doi: 10.1080/13550280152537238.
To explore the respective roles of highly active antiretroviral therapy (HAART) and alpha-interferon in improving survival of patients with AIDS-related PML, we retrospectively analyzed all patients with AIDS and PML who were referred to Johns Hopkins University HIV Neurology Program from 1985 to 2000. For 97 evaluable patients, we compared survival of those who were on HAART (three or more antiretroviral drugs) to those who were not on HAART. The effect of alpha-interferon was also studied. Multivariate analysis showed no difference in survival among patients on none, one, or two forms of antiretrovirals; however, survival was significantly greater for those on HAART. Whereas alpha-interferon use was shown to be associated with longer survival (P < 0.057), this effect was not independent of the effects of HAART. HAART significantly increases survival for patients with PML and AIDS; however, alpha-interferon does not appear to provide additional benefit.
为探讨高效抗逆转录病毒治疗（HAART）和α干扰素在提高艾滋病相关进行性多灶性白质脑病（PML）患者生存率方面的各自作用，我们回顾性分析了1985年至2000年间转诊至约翰霍普金斯大学HIV神经学项目的所有艾滋病合并PML患者。对于97例可评估患者，我们比较了接受HAART（三种或更多抗逆转录病毒药物）治疗的患者与未接受HAART治疗的患者的生存率。同时也研究了α干扰素的作用。多变量分析显示，未接受抗逆转录病毒药物治疗、接受一种或两种抗逆转录病毒药物治疗的患者在生存率上无差异；然而，接受HAART治疗的患者生存率显著更高。虽然使用α干扰素与更长的生存期相关（P < 0.057），但这种作用并非独立于HAART的作用。HAART显著提高了PML合并艾滋病患者的生存率；然而，α干扰素似乎并未提供额外的益处。
